Clinical trials: APOL1 Associated Kidney Disease
Nephrotic Syndrome, Focal Segmental Glomerulosclerosis
Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1
This is a multicentric retrospective observational cohort study. As primary objective, the study aims to evaluate the factors associated with nephrotic syndrome remission in patient with nephrotic syndrome, biopsy-prove minimal…
- Conditions
- Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, APOL1 Associated Kidney Disease
- Trial name
- NEPHROL1 (NCT06443034)
- Where
- France
- Volunteers
- 124 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Kidney Disease
ACTH Treatment of APOL1- Associated Nephropathy
The purpose of this research study is to determine if the study drug H.C. Acthar gel slows the progression of your kidney disease.
- Trial name
- NCT02006849
- Testing
- Acthar
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Genetic Predisposition, Chronic Kidney Diseases
APOL1 Genetic Testing in African Americans
Recent breakthroughs in medical genetics have discovered that a portion of kidney failure affecting the Black community is mediated by coding variants in a gene called apolipoprotein L1 (APOL1) - and that genetic variants, not…
- Conditions
- Genetic Predisposition, Chronic Kidney Diseases, Nephropathy, APOL1 Associated Kidney Disease
- Trial name
- NCT05656261
- Testing
- Assessment of the frequency of APOL-1 renal risk variant in the black population, and evaluating their attitudes about genetic testing and APOL1 genotype via self-administered surveys
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- St. Louis University
Chronic Kidney Diseases
Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease
The purpose of this study is to determine if the drug, baricitinib, is safe and effective in reducing high levels of albumin in the urine (albuminuria) in African American/Blacks with APOL1- associated focal segmental…
- Trial name
- JUSTICE (NCT05237388)
- Testing
- Baricitinib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Duke University